These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34627448)

  • 1. [The Expression and Significance of Serum Protein ROCK2 in Patients with Chronic Graft-Versus-Host Disease].
    Tang P; Zheng CH; Dong ZK; Xie MH; Xie XS; Sun H; Sun L; Wan DM; Liu YF; Jiang ZX; Guo R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1606-1609. PubMed ID: 34627448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
    Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 4. The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study.
    Wang B; Liang Z; Liu W; Sun Y; Cen X; Dong Y; Ren H
    Clin Transplant; 2020 Jul; 34(7):e13865. PubMed ID: 32242991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Toubai T; Hosokawa Y
    Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
    Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
    Front Immunol; 2020; 11():1505. PubMed ID: 32849514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
    Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
    Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang HT; Zhao XY; Zhao XS; Han TT; Lv M; Chang YJ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):679-84. PubMed ID: 23978019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.
    Zanin-Zhorov A; Blazar BR
    Clin Immunol; 2021 Sep; 230():108823. PubMed ID: 34400321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belumosudil for chronic graft-versus-host disease.
    Taylor B; Cohen J; Tejeda J; Wang TP
    Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
    J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.